New combo therapy tested to keep advanced lung cancer at bay
NCT ID NCT03559049
Summary
This study tested whether adding a pill called rucaparib to an existing immunotherapy (pembrolizumab) could help control stage IV non-squamous lung cancer for longer after initial chemotherapy. It aimed to see if this two-drug maintenance therapy was safe and could delay cancer progression in 25 patients whose cancer had not worsened after first-line treatment. The trial was terminated early and did not complete its planned enrollment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IV NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
The University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, 48109, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.